Eli Lilly and Co. (NYSE: LLY) recently announced it will soon roll out its Tempo personalized diabetes management platform in the U.S. The pharma giant described Tempo as its first connected platform. It includes three components: the Tempo Smart Button, a compatible TempSmart app, and the prefilled Tempo Pen insulin pen. The goal is personalized […]
Eli Lilly
Glooko adds former Eli Lilly exec to its board of directors
Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors. Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units. According to a news release, […]
Eli Lilly to build $1B manufacturing facility for injectable products, devices in North Carolina
Eli Lilly (NYSE:LLY) announced today that it plans to invest more than $1 billion to create a new manufacturing site in North Carolina. Indianapolis-based Eli Lilly’s new facility, which it expects will create nearly 600 jobs in Concord, North Carolina, will manufacture parenteral (injectable) products and devices while increasing the company’s manufacturing capacity. The company […]
Lilly pays $50 million upfront to use Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology
Eli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology. Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products intended for the nervous system. Lilly is optimistic that Fusogenix could help it address hurdles tied to nucleic acid therapeutic modalities. Get the full story […]
Your favorite articles from Drug Delivery Business News in 2021
From continuous glucose monitors to insulin pens, plus needle-free injection devices and inhalers — here are the most popular articles on Drug Delivery Business News from 2021: Links to your favorite articles: Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’ Eli Lilly partners with four companies on insulin pen tech Scancell picks PharmaJet’s needle-free […]
7 diabetes treatment innovations to look out for on World Diabetes Day
World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes. This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease. Some of those treatments involve insulin, which was discovered as a treatment for diabetes in […]
Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes
Eli Lilly (NYSE:LLY) announced positive results from a trial comparing tirzepatide to titrated insulin glargine in adults with type 2 diabetes. Indianapolis-based Eli Lilly’s Surpass-4 clinical trial demonstrated that adults with type 2 diabetes and increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared […]
Eli Lilly to donate nearly $1M to Type 1 diabetes initiative
Eli Lilly (NYSE:LLY) announced today that it will commit nearly $1 million over the next three years toward helping children with Type 1 diabetes. Indianapolis-based Eli Lilly, in a joint effort with the Leona M. and Harry B. Helmsley Charitable Trust, seeks to promote greater access to care and resources while inspiring confidence for children […]
Eli Lilly forms neuroscience and immunology units amid leadership changes
Eli Lilly (NYSE:LLY) today announced executive leadership changes as it creates neuroscience and immunology business units. Indianapolis-based Eli Lilly split its bio-medicines segment into Lilly Neuroscience and Lilly Immunology in the organizational shift, to be made effective Sept. 5, with Anne White set to lead the neuroscience unit and Patrik Jonsson set to head up […]
FDA approves, expands label for Eli Lilly’s rapid-acting insulin for infusion
Eli Lilly (NYSE:LLY) announced today that it received FDA approval and expanded labeling for its Lyumjev rapid-acting insulin. Indianapolis-based Eli Lilly’s Lyumjev (insulin lispro-aabc injection) 100 units/mL holds indication to improve glycemic control in adults with type 1 and type 2 diabetes, including administration via continuous subcutaneous insulin infusion (CSII) with an insulin pump. The […]
